CORONA, Calif. (AP) — Watson Pharmaceuticals Inc. said Friday it will pay $18 million to Elan Corp. PLC to settle a patent lawsuit over Watson’s generic version of pain reliever Naprelan, or naproxen sodium tablets. Watson also agreed not to marke t or sell its naproxen sodium product until the expiration of the patent on the drug. It did not say when the patent would expire, be found invalid or unenforceable.
Related Articles Read More >

Confidently navigate the transition from bench to batch

FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
